

AGIOS PHARMACEUTICALS INC  
Form 8-K  
December 06, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 4, 2016**

**Agios Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**88 Sidney Street, Cambridge, MA**

**001-36014**  
**(Commission**

**File Number)**

**26-0662915**  
**(IRS Employer**

**Identification No.)**

**02139**

Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)  
Registrant's telephone number, including area code: (617) 649-8600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On December 4, 2016, Agios Pharmaceuticals, Inc. (the Company ) issued a press release announcing new clinical data from both the Company s ongoing phase 2 DRIVE PK study evaluating AG-348 in patients with pyruvate kinase deficiency and the Company s ongoing phase 1 single ascending dose and multiple ascending dose study of AG-519 in healthy volunteers. On December 5, 2016, the Company issued a press release announcing new clinical data from the dose escalation portion of the Company s ongoing phase 1 study evaluating single agent AG-120 in patients with isocitrate dehydrogenase-1 mutant positive advanced hematologic malignancies. The Company presented these data at the 2016 American Society of Hematology Annual Meeting and Exposition taking place December 3-6, 2016 in San Diego, California.

The full text of the press releases issued in connection with these announcements are attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibits are included in this report:

Exhibit No.	Description
99.1	Press release issued by Agios Pharmaceuticals, Inc. on December 4, 2016.
99.2	Press release issued by Agios Pharmaceuticals, Inc. on December 5, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AGIOS PHARMACEUTICALS, INC.

Date: December 6, 2016

By: /s/ David P. Schenkein  
David P. Schenkein, M.D.

President and Chief Executive Officer

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press release issued by Agios Pharmaceuticals, Inc. on December 4, 2016.
99.2	Press release issued by Agios Pharmaceuticals, Inc. on December 5, 2016.